FCGR3A and cancer: In vivo, a specific IgG monoclonal antibody can engage via its Fab region with its target antigen on a cancer cell; simultaneously, the Fc region of the monoclonal antibody is recognized by CD16, facilitating the activation of cytotoxic NK cell functions.